{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=9", "query": { "condition": "Stage IV Skin Melanoma", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 654, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:38:44.872Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03132675", "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III/IV Melanoma" ], "interventions": [ { "name": "tavokinogene telseplasmid", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ImmunoPulse", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "OncoSec Medical Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2017-10-03", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2023-03-27", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 23, "location_summary": "Tucson, Arizona • Yuma, Arizona • La Jolla, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132675" }, { "nct_id": "NCT01807182", "title": "Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Therapeutic Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08-20", "completion_date": "2021-08-26", "has_results": true, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807182" }, { "nct_id": "NCT04588246", "title": "Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Breast Neoplasm", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Brain Neoplasm", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Memantine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-08-05", "completion_date": "2024-08-06", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 79, "location_summary": "Tucson, Arizona • Corona, California • Duarte, California + 63 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588246" }, { "nct_id": "NCT00329641", "title": "Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2011-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329641" }, { "nct_id": "NCT04562129", "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Inoperable Disease" ], "interventions": [ { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-09-24", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562129" }, { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT03765229", "title": "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 11, "start_date": "2019-03-22", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03765229" }, { "nct_id": "NCT00138229", "title": "Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-07", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-03-29", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138229" }, { "nct_id": "NCT00020267", "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Adult Soft Tissue Sarcoma", "Colorectal Cancer", "Bone Cancer", "Ovarian Sarcoma", "Melanoma", "Colon Cancer", "Rectal Cancer", "Breast Cancer", "Eye Cancer", "Uterine Sarcoma" ], "interventions": [ { "name": "interleukin-2", "type": "DRUG" }, { "name": "MAGE-12 peptide vaccine", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020267" }, { "nct_id": "NCT00005968", "title": "Irofulven in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "irofulven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-14T01:38:44.872Z", "location_count": 5, "location_summary": "Santa Monica, California • Denver, Colorado • Park Ridge, Illinois + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005968" } ] }